Wanbury Limited Asset Resilience Ratio
Wanbury Limited asset resilience ratio. Wanbury Limited (WANBURY) has an Asset Resilience Ratio of 3.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Wanbury Limited fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Wanbury Limited (2006–2025)
Asset resilience ratio of Wanbury Limited from 2006 to 2025. This chart shows how Wanbury Limited's Asset Resilience Ratio has changed over time. Read Wanbury Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Wanbury Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Wanbury Limited balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs58.77 Million | 1.29% |
| Short-term Investments | Rs86.71 Million | 1.9% |
| Total Liquid Assets | Rs145.48 Million | 3.19% |
Asset Resilience Insights
- Limited Liquidity: Wanbury Limited maintains only 3.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wanbury Limited Industry Peers by Asset Resilience Ratio
Compare Wanbury Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Wanbury Limited Asset Resilience Ratio by Year (2006–2025)
Wanbury Limited asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Wanbury Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 4.78% | Rs197.70 Million ≈ $2.14 Million |
Rs4.14 Billion ≈ $44.76 Million |
+4.05pp |
| 2024-03-31 | 0.73% | Rs24.97 Million ≈ $270.03K |
Rs3.43 Billion ≈ $37.15 Million |
-1.15pp |
| 2023-03-31 | 1.88% | Rs57.06 Million ≈ $617.06K |
Rs3.04 Billion ≈ $32.82 Million |
-4.55pp |
| 2022-03-31 | 6.43% | Rs226.56 Million ≈ $2.45 Million |
Rs3.53 Billion ≈ $38.13 Million |
+2.92pp |
| 2021-03-31 | 3.50% | Rs101.31 Million ≈ $1.10 Million |
Rs2.89 Billion ≈ $31.27 Million |
-5.85pp |
| 2020-03-31 | 9.36% | Rs260.73 Million ≈ $2.82 Million |
Rs2.79 Billion ≈ $30.14 Million |
+9.51pp |
| 2019-03-31 | -0.15% | Rs-4.41 Million ≈ $-47.70K |
Rs2.86 Billion ≈ $30.93 Million |
-0.01pp |
| 2018-03-31 | -0.14% | Rs-3.88 Million ≈ $-42.00K |
Rs2.73 Billion ≈ $29.49 Million |
+3.49pp |
| 2017-03-31 | -3.64% | Rs-149.81 Million ≈ $-1.62 Million |
Rs4.12 Billion ≈ $44.55 Million |
-3.64pp |
| 2016-03-31 | 0.00% | Rs94.00K ≈ $1.02K |
Rs3.82 Billion ≈ $41.35 Million |
-0.28pp |
| 2012-03-31 | 0.28% | Rs22.99 Million ≈ $248.61K |
Rs8.11 Billion ≈ $87.71 Million |
-0.07pp |
| 2007-03-31 | 0.35% | Rs11.30 Million ≈ $122.17K |
Rs3.20 Billion ≈ $34.65 Million |
-5.97pp |
| 2006-03-31 | 6.32% | Rs123.28 Million ≈ $1.33 Million |
Rs1.95 Billion ≈ $21.08 Million |
-- |
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more